{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:52:30Z","timestamp":1785455550897,"version":"3.56.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.cct.2022.106704","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T17:23:40Z","timestamp":1644341020000},"page":"106704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome"],"prefix":"10.1016","volume":"114","author":[{"given":"Jeffrey L.","family":"Neul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan K.","family":"Percy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Benke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Berry-Kravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Glaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarika U.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cct.2022.106704_bb0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.cct.2022.106704_bb0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1651-2227.1985.tb10993.x","article-title":"Rett\u2019s syndrome: prevalence and impact on progressive severe mental retardation in girls","volume":"74","author":"Hagberg","year":"1985","journal-title":"Acta Paediatr. Scand."},{"issue":"17","key":"10.1016\/j.cct.2022.106704_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179610","article-title":"MECP2-related disorders in males","volume":"22","author":"Pascual-Alonso","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cct.2022.106704_bb0020","author":"International Rett Syndrome Foundation"},{"issue":"10","key":"10.1016\/j.cct.2022.106704_bb0025","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1007\/s10803-015-2519-1","article-title":"Brief report: systematic review of Rett syndrome in males","volume":"45","author":"Reichow","year":"2015","journal-title":"J. Autism Dev. Disord."},{"issue":"1","key":"10.1016\/j.cct.2022.106704_bb0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajmg.b.32707","article-title":"The array of clinical phenotypes of males with mutations in Methyl-CpG binding protein 2","volume":"180","author":"Neul","year":"2019","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"1","key":"10.1016\/j.cct.2022.106704_bb0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1866-1955-6-20","article-title":"Developmental delay in Rett syndrome: data from the natural history study","volume":"6","author":"Neul","year":"2014","journal-title":"J. Neurodev. Disord."},{"issue":"6","key":"10.1016\/j.cct.2022.106704_bb0040","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ana.22124","article-title":"RettSearch Consortium, Rett syndrome: revised diagnostic criteria and nomenclature","volume":"68","author":"Neul","year":"2010","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.cct.2022.106704_bb0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/mrdd.10020","article-title":"Clinical manifestations and stages of Rett syndrome","volume":"8","author":"Hagberg","year":"2002","journal-title":"Ment. Retard. Dev. Disabil. Res. Rev."},{"issue":"S1","key":"10.1016\/j.cct.2022.106704_bb0050","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ajmg.1320250506","article-title":"Rett syndrome: a suggested staging system for describing impairment profile with increasing age towards adolescence","volume":"25","author":"Hagberg","year":"1986","journal-title":"Am. J. Med. Genet. Suppl."},{"key":"10.1016\/j.cct.2022.106704_bb0055","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.neubiorev.2019.01.028","article-title":"Regression in Rett syndrome: developmental pathways to its onset","volume":"98","author":"Einspieler","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"4","key":"10.1016\/j.cct.2022.106704_bb0060","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.ridd.2013.01.014","article-title":"Changing the perspective on early development of Rett syndrome","volume":"34","author":"Marschik","year":"2013","journal-title":"Res. Dev. Disabil."},{"issue":"6","key":"10.1016\/j.cct.2022.106704_bb0065","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1073\/pnas.0812394106","article-title":"Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice","volume":"106","author":"Tropea","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1\u20132","key":"10.1016\/j.cct.2022.106704_bb0070","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jns.2008.12.003","article-title":"NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke","volume":"278","author":"Bickerdike","year":"2009","journal-title":"J. Neurol. Sci."},{"issue":"16","key":"10.1016\/j.cct.2022.106704_bb0075","doi-asserted-by":"crossref","first-page":"e1912","DOI":"10.1212\/WNL.0000000000007316","article-title":"Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome","volume":"92","author":"Glaze","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.cct.2022.106704_bb0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2017.07.002","article-title":"A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome","volume":"76","author":"Glaze","year":"2017","journal-title":"Pediatr. Neurol."},{"issue":"13","key":"10.1016\/j.cct.2022.106704_bb0085","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1177\/0883073815579707","article-title":"Improving treatment trial outcomes for Rett syndrome: the development of Rett-specific anchors for the Clinical Global Impression Scale","volume":"30","author":"Neul","year":"2015","journal-title":"J. Child Neurol."},{"issue":"8","key":"10.1016\/j.cct.2022.106704_bb0090","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/1469-7610.00236","article-title":"The Rett Syndrome Behaviour Questionnaire (RSBQ): refining the behavioural phenotype of Rett syndrome","volume":"43","author":"Mount","year":"2002","journal-title":"J. Child Psychol. Psychiatry"},{"issue":"12","key":"10.1016\/j.cct.2022.106704_bb0095","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1073\/pnas.1311141111","article-title":"Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome","volume":"111","author":"Khwaja","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.cct.2022.106704_bb0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/acn3.533","article-title":"Placebo-controlled crossover assessment of mecasermin for the treatment of Rett syndrome","volume":"5","author":"O'Leary","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.cct.2022.106704_bb0105","author":"Anagnostou"},{"key":"10.1016\/j.cct.2022.106704_bb0110","author":"Anavex Life Sciences Corp"},{"key":"10.1016\/j.cct.2022.106704_bb0115","author":"Anavex Life Sciences Corp"},{"key":"10.1016\/j.cct.2022.106704_bb0120","author":"Anavex Life Sciences Corp"},{"key":"10.1016\/j.cct.2022.106704_bb0125","author":"GW Research Ltd"},{"issue":"1","key":"10.1016\/j.cct.2022.106704_bb0130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s11689-015-9127-4","article-title":"Anxiety-like behavior in Rett syndrome: characteristics and assessment by anxiety scales","volume":"7","author":"Barnes","year":"2015","journal-title":"J. Neurodev. Disord."},{"issue":"1","key":"10.1016\/j.cct.2022.106704_bb0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s11689-015-9104-y","article-title":"A national survey of Rett syndrome: behavioural characteristics","volume":"7","author":"Cianfaglione","year":"2015","journal-title":"J. Neurodev. Disord."},{"issue":"2","key":"10.1016\/j.cct.2022.106704_bb0140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ajmg.b.30270","article-title":"The association between behavior and genotype in Rett syndrome using the Australian Rett Syndrome Database","volume":"141B","author":"Robertson","year":"2006","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"6","key":"10.1016\/j.cct.2022.106704_bb0145","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1365-2753.2007.00921.x","article-title":"The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use","volume":"14","author":"Berk","year":"2008","journal-title":"J. Eval. Clin. Pract."},{"issue":"3","key":"10.1016\/j.cct.2022.106704_bb0150","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.comppsych.2008.08.005","article-title":"The Clinical Global Impressions scale: errors in understanding and use","volume":"50","author":"Busner","year":"2009","journal-title":"Compr. Psychiatry"},{"issue":"2","key":"10.1016\/j.cct.2022.106704_bb0155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.tins.2015.12.008","article-title":"Rett syndrome: crossing the threshold to clinical translation","volume":"39","author":"Katz","year":"2016","journal-title":"Trends Neurosci."},{"issue":"10","key":"10.1016\/j.cct.2022.106704_bb0160","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/21678707.2016.1229181","article-title":"Neurobiologically-based treatments in Rett syndrome: opportunities and challenges","volume":"4","author":"Kaufmann","year":"2016","journal-title":"Expert Opin. Orphan Drugs"},{"issue":"7","key":"10.1016\/j.cct.2022.106704_bb0165","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/DBP.0b013e31829d1f20","article-title":"Outcome Measures Working Groups, Outcome measures for clinical trials in fragile X syndrome","volume":"34","author":"Berry-Kravis","year":"2013","journal-title":"J. Dev. Behav. Pediatr."},{"issue":"4","key":"10.1016\/j.cct.2022.106704_bb0170","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40265-016-0542-y","article-title":"Pharmacotherapy for fragile X syndrome: progress to date","volume":"76","author":"Davenport","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.cct.2022.106704_bb0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s11689-017-9193-x","article-title":"Updated report on tools to measure outcomes of clinical trials in fragile X syndrome","volume":"9","author":"Budimirovic","year":"2017","journal-title":"J. Neurodev. Disord."},{"issue":"5","key":"10.1016\/j.cct.2022.106704_bb0180","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Research Units on Pediatric Psychopharmacology Autism Network, Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2022.106704_bb0185","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"issue":"6","key":"10.1016\/j.cct.2022.106704_bb0190","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1044\/2015_JSLHR-L-14-0185","article-title":"An exploration of the use of eye gaze and gestures in females with Rett syndrome","volume":"59","author":"Urbanowicz","year":"2016","journal-title":"J. Speech Lang Hear Res."},{"issue":"6","key":"10.1016\/j.cct.2022.106704_bb0195","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1044\/1092-4388(2002\/097)","article-title":"Validity and reliability of the communication and symbolic behavior scales developmental profile with very young children","volume":"45","author":"Wetherby","year":"2002","journal-title":"J. Speech Lang Hear Res."},{"issue":"5","key":"10.1016\/j.cct.2022.106704_bb0200","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/1362361314542955","article-title":"Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder","volume":"19","author":"Anagnostou","year":"2015","journal-title":"Autism"},{"issue":"2","key":"10.1016\/j.cct.2022.106704_bb0205","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10882-009-9168-2","article-title":"Communication in individuals with Rett syndrome: an assessment of forms and functions","volume":"22","author":"Didden","year":"2010","journal-title":"J. Dev. Phys. Disabil."},{"issue":"1","key":"10.1016\/j.cct.2022.106704_bb0210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/17518423.2013.879940","article-title":"Parental perspectives on the communication abilities of their daughters with Rett syndrome","volume":"19","author":"Urbanowicz","year":"2016","journal-title":"Dev. Neurorehabil."},{"issue":"4","key":"10.1016\/j.cct.2022.106704_bb0215","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s10803-017-3034-3","article-title":"Assessment of caregiver inventory for Rett syndrome","volume":"47","author":"Lane","year":"2017","journal-title":"J. Autism Dev. Disord."},{"issue":"6","key":"10.1016\/j.cct.2022.106704_bb0220","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/geront\/29.6.798","article-title":"Application of a multidimensional caregiver burden inventory","volume":"29","author":"Novak","year":"1989","journal-title":"Gerontologist"},{"issue":"3","key":"10.1016\/j.cct.2022.106704_bb0225","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1469-8749.2003.tb00923.x","article-title":"Assessing the impact of pediatric epilepsy and concomitant behavioral, cognitive, and physical\/neurologic disability: impact of Childhood Neurologic Disability Scale","volume":"45","author":"Camfield","year":"2003","journal-title":"Dev. Med. Child Neurol."},{"issue":"6","key":"10.1016\/j.cct.2022.106704_bb0230","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ana.22154","article-title":"Rett syndrome diagnostic criteria: lessons from the Natural History Study","volume":"68","author":"Percy","year":"2010","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.cct.2022.106704_bb0235","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ajmg.a.36871","article-title":"Aspects of speech-language abilities are influenced by MECP2 mutation type in girls with Rett syndrome","volume":"167A","author":"Urbanowicz","year":"2015","journal-title":"Am. J. Med. Genet. A"},{"issue":"4","key":"10.1016\/j.cct.2022.106704_bb0240","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2788.1993.tb00885.x","article-title":"A longitudinal study of cognitive skills and communication behaviours in children with Rett syndrome","volume":"37","author":"Woodyatt","year":"1993","journal-title":"J. Intellect. Disabil. Res."},{"issue":"1","key":"10.1016\/j.cct.2022.106704_bb0245","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1088357610380042","article-title":"Communication skills in girls with Rett syndrome","volume":"26","author":"Bartolotta","year":"2011","journal-title":"Focus Autism Other Dev. Disabl."},{"key":"10.1016\/j.cct.2022.106704_bb0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pediatrneurol.2017.05.025","article-title":"Defining hand stereotypies in Rett syndrome: a movement disorders perspective","volume":"75","author":"Dy","year":"2017","journal-title":"Pediatr. Neurol."},{"issue":"3","key":"10.1016\/j.cct.2022.106704_bb0255","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/17518423.2012.758183","article-title":"Perspectives on hand function in girls and women with Rett syndrome","volume":"17","author":"Downs","year":"2014","journal-title":"Dev. Neurorehabil."},{"issue":"3","key":"10.1016\/j.cct.2022.106704_bb0260","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/0883073810381920","article-title":"Longitudinal hand function in Rett syndrome","volume":"26","author":"Downs","year":"2011","journal-title":"J. Child Neurol."},{"issue":"9","key":"10.1016\/j.cct.2022.106704_bb0265","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1469-8749.2010.03636.x","article-title":"Level of purposeful hand function as a marker of clinical severity in Rett syndrome","volume":"52","author":"Downs","year":"2010","journal-title":"Dev. Med. Child Neurol."},{"issue":"1","key":"10.1016\/j.cct.2022.106704_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147555","article-title":"Validating the Rett Syndrome Gross Motor Scale","volume":"11","author":"Downs","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.cct.2022.106704_bb0275","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/mds.870050303","article-title":"Rett syndrome and associated movement disorders","volume":"5","author":"FitzGerald","year":"1990","journal-title":"Mov. Disord."},{"issue":"16","key":"10.1016\/j.cct.2022.106704_bb0280","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1212\/01.wnl.0000291011.54508.aa","article-title":"Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome","volume":"70","author":"Neul","year":"2008","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.cct.2022.106704_bb0285","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1080\/09638288.2016.1212280","article-title":"Building the repertoire of measures of walking in Rett syndrome","volume":"39","author":"Stahlhut","year":"2017","journal-title":"Disabil. Rehabil."},{"issue":"9","key":"10.1016\/j.cct.2022.106704_bb0290","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s10803-006-0293-9","article-title":"Development of a video-based evaluation tool in Rett syndrome","volume":"37","author":"Fyfe","year":"2007","journal-title":"J. Autism Dev. Disord."},{"issue":"1","key":"10.1016\/j.cct.2022.106704_bb0295","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijdevneu.2019.01.001","article-title":"Spoken word processing in Rett syndrome: evidence from event-related potentials","volume":"73","author":"Key","year":"2019","journal-title":"Int. J. Dev. Neurosci."},{"issue":"7","key":"10.1016\/j.cct.2022.106704_bb0300","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/09638288.2016.1277392","article-title":"Choice making in Rett syndrome: a descriptive study using video data","volume":"40","author":"Urbanowicz","year":"2018","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.cct.2022.106704_bb0305","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ridd.2018.04.004","article-title":"Response to name and its value for the early detection of developmental disorders: insights from autism spectrum disorder, Rett syndrome, and fragile X syndrome","volume":"82","author":"Zhang","year":"2018","journal-title":"A perspectives paper, Res. Dev. Disabil."},{"key":"10.1016\/j.cct.2022.106704_bb0310","series-title":"Vineland Adaptive Behavior Scales, Second Edition (Vineland-II)","author":"Sparrow","year":"2005"},{"key":"10.1016\/j.cct.2022.106704_bb0315","series-title":"Mullen Scales of Early Learning","author":"Mullen","year":"1995"},{"key":"10.1016\/j.cct.2022.106704_bb0320","series-title":"Bayley 4 Clinical Use and Interpretation","author":"Aylward","year":"2020"},{"key":"10.1016\/j.cct.2022.106704_bb0325","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pediatrneurol.2019.03.005","article-title":"A new scale to evaluate motor function in Rett syndrome: validation and psychometric properties","volume":"100","author":"Rodocanachi Roidi","year":"2019","journal-title":"Pediatr. Neurol."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714422000301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714422000301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:54:36Z","timestamp":1761555276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714422000301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":65,"alternative-id":["S1551714422000301"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2022.106704","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2022.106704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106704"}}